Agios Pharma (AGIO) Presents Translational Data to Further Characterize the Role of TIBSOVO Treatment in IDH1 Mutant AML

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Agios Pharma (AGIO) Presents Translational Data to Further Characterize the Role of TIBSOVO Treatment in IDH1 Mutant AML

Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

December 9, 2019 8:00 AM EST

Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML

Mechanisms of Resistance and Relapse to Single Agent IDH1 Inhibitors Are Complex and Multiclonal and Include Both IDH-dependent and IDH-independent Pathways

Company to Host Investor Event and Webcast Today at 8:00 p.m. ET 

ORLANDO, Fla., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented translational data describing deep and... More